Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: The CRUCIAL study

Postgraduate Medicine

Volumn 122, Issue 2, 2010, Pages 7-15

  Zamorano, José ^a   Erdine, Serap ^b   Lopez, Abel Pavia ^c   Kim, Jae Hyung ^d   Khadra, Ayman Al ^e   Westergaard, Mogens ^f   Sutradhar, Santosh ^f   Yunis, Carla ^f  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b ISTANBUL UNIVERSITY   (Turkey)

^c HOSPITAL GENERAL DE MÉXICO   (Mexico)

^d The Catholic University of Korea   (South Korea)

^e PRINCE SULTAN CARDIAC CENTER   (Saudi Arabia)

^f PFIZER INC   (United States)

Author keywords

Antihypertensive therapy; Cardiovascular risk; Clinical trial; CRUCIAL trial; Hypertension; Primary prevention; Single pill

Indexed keywords

AMLODIPINE PLUS ATORVASTATIN; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; AMLODIPINE; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

AGE; ARTICLE; ASIA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL PRACTICE; DYSLIPIDEMIA; ECG ABNORMALITY; EUROPE; FAMILY HISTORY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MEDICAL DECISION MAKING; MEDICAL HISTORY; MEDICAL RESEARCH; METHODOLOGY; MIDDLE EAST; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; PATIENT SELECTION; PERIPHERAL VASCULAR DISEASE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; SAMPLE SIZE; SOUTH AND CENTRAL AMERICA; STATISTICAL ANALYSIS; STROKE; SYSTEMATIC ERROR; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; ADULT; AGED; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CLUSTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; HYPERCHOLESTEROLEMIA; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; MULTICENTER STUDY; PRIMARY PREVENTION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; DRUG EFFICACY; DRUG SAFETY; HYPERLIPIDEMIA; PATIENT CARE; PRACTICE GUIDELINE; STUDY DESIGN; TREATMENT DURATION; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; AMLODIPINE; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CLUSTER ANALYSIS; DRUG COMBINATIONS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTERNATIONALITY; MALE; MIDDLE AGED; PRIMARY PREVENTION; PROSPECTIVE STUDIES; PYRROLES; QUESTIONNAIRES; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS;

EID: 79953692440     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.03.2117     Document Type: Article

References (31)

1. Ezzati M, Hoorn SV, Lopez AD, et al. Comparative quantification of mortality and burden of disease attributable to selected risk factors. Chapter 4 in WHO 2006 Report: Global Burden of Disease and Risk Factors. http://www.dcp2.org/pubs/GBD Accessed December 16, 2009.
2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
3. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007;28(19):2375-2414.
4. Conroy RM, Pyörälä K, Fitzgerald AP, et al; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987-1003.
5. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847.
6. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16(2):121-137.
7. Wong ND, Lopez V, Tang S, Williams GR. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol. 2006;98(2):204-208.
8. Benner JS, Smith TW, Petrilla AA, et al. Estimated prevalence of uncontrolled hypertension and multiple cardiovascular risk factors and their associated risk of coronary heart disease in the United States. J Am Soc Hypertens. 2008;2(1):44-53.
9. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997.
10. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-696.
11. Julius S, Kjeldsen SE, Weber M, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-2031.
12. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-1158.
13. Emberson J, Whincup P, Morris R, Walker M, Ebrahim S. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J. 2004;25(6):484-491.
14. Ogedegbe G. Barriers to optimal hypertension control. J Clin Hypertens (Greenwich). 2008;10(8):644-646.
15. Benner JS, Chapman RH, Petrilla AA, Tang SS, Rosenberg N, Schwartz JS. Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am J Health Syst Pharm. 2009;66(16):1471-1477.
16. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155(4):772-779.
17. Agarwal S, Tang SS, Rosenberg N, et al. Does synchronizing initiation of therapy affect adherence to concomitant use of antihypertensive and lipid-lowering therapy? Am J Ther. 2009;16(2):119-126.
18. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-719.
19. Patel BV, Leslie RS, Thiebaud P, et al. Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag. 2008;4(3):673-681.
20. McKeage K, Siddiqui MA. Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia. Am J Cardiovasc Drugs. 2008;8(1):51-67.
21. Sever P, Dahlöf B, Poulter N, et al; ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006;27(24):2982-2988.
22. Medical Research Council. MRC cluster randomized trials: methodological and ethical considerations. London, England: Medical Research Council; November 2002.
23. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES) 1999/2000. National Center for Health Statistics http://www.cdc.gov/nchs/nhanes.html. Accessed November 30, 2009.
24. Torgerson DJ. Contamination in trials: is cluster randomisation the answer? BMJ. 2001;322(7282):355-357.
25. De Backer G, Ambrosioni E, Borch-Johnsen K, et al; European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2003;10(4): S1-S10.
26. Park J. 2004 Korean Hypertension Treatment Guideline and Its Perspective. Korean Circ J. 2006;36(6):405-410.
27. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-753.
28. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22(3):312-318.
29. Benner JS, Erhardt L, Flammer M, et al; REACH OUT Investigators. A novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients' modifiable risk factor profile. Int J Clin Pract. 2008;62(10):1484-1498.
30. Maruthur NM, Wang NY, Appel LJ. Lifestyle interventions reduce coronary heart disease risk: results from the PREMIER Trial. Circulation. 2009;119(15):2026-2031.
31. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419-1423.